Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
The Journal of Infectious Diseases|July 23, 2018
The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined AnalysisÁlvaro H Borges, Jacqueline Neuhaus, Shweta Sharma, et al.
AIDS (London, England)|November 5, 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenZoe Fox, Andrew Phillips, Cal Cohen, et al.
International Journal of STD & AIDS|July 30, 2008
Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited settingSomsamorn Mangclaviraj, Stephen J Kerr, Surasith Chaithongwongwatthana, et al.
Clinical Trials (London, England)|December 6, 2014
The impact of registration of clinical trials units: the UK experienceEleanor McFadden, Saeeda Bashir, Steve Canham, et al.
Scientific Reports|September 9, 2017
Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individualsDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Clinical and Vaccine Immunology : CVI|October 20, 2006
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samplesWayne B Dyer, Sarah L Pett, John S Sullivan, et al.
Antiviral Therapy|March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic, Allison Martin, Dianne Carey, et al.
AIDS (London, England)|January 26, 2005
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited settingChris Duncombe, Stephen J Kerr, Kiat Ruxrungtham, et al.
AIDS (London, England)|July 1, 2011
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern AfricaGail V Matthews, Prince Manzini, Zonghui Hu, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
The Journal of Infectious Diseases|July 23, 2018
The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined AnalysisÁlvaro H Borges, Jacqueline Neuhaus, Shweta Sharma, et al.
AIDS (London, England)|November 5, 2008
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimenZoe Fox, Andrew Phillips, Cal Cohen, et al.
International Journal of STD & AIDS|July 30, 2008
Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited settingSomsamorn Mangclaviraj, Stephen J Kerr, Surasith Chaithongwongwatthana, et al.
Clinical Trials (London, England)|December 6, 2014
The impact of registration of clinical trials units: the UK experienceEleanor McFadden, Saeeda Bashir, Steve Canham, et al.
Scientific Reports|September 9, 2017
Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individualsDaniel D Murray, Kazuo Suzuki, Matthew Law, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 8, 2007
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulationAlan Winston, Patrick W G Mallon, Claudette Satchell, et al.
Clinical and Vaccine Immunology : CVI|October 20, 2006
Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samplesWayne B Dyer, Sarah L Pett, John S Sullivan, et al.
Antiviral Therapy|March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic, Allison Martin, Dianne Carey, et al.
AIDS (London, England)|January 26, 2005
HIV disease progression in a patient cohort treated via a clinical research network in a resource limited settingChris Duncombe, Stephen J Kerr, Kiat Ruxrungtham, et al.
AIDS (London, England)|July 1, 2011
Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern AfricaGail V Matthews, Prince Manzini, Zonghui Hu, et al.
Pageof 14